CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
Del Campo M, Quesada C, Vermunt L, Peeters CFW, Hok-A-Hin YS, Trieu C, Braber AD, Verberk IMW, Visser PJ, Tijms BM, van der Flier WM, Teunissen CE
Abstract
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.
Reference
Del Campo M, Quesada C, Vermunt L, Peeters CFW, Hok-A-Hin YS, Trieu C, Braber AD, Verberk IMW, Visser PJ, Tijms BM, van der Flier WM, Teunissen CE. CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals. Mol Neurodegener. 2024 Nov 11;19(1):82. doi: 10.1186/s13024-024-00767-z. PMID: 39523360; PMCID: PMC11552178.
